An audit of research productivity in clinical biochemistry revisited. [PDF]
JRSM Open, 2019 Reynolds TM, Wierzbicki AS.
europepmc +1 more source
Textbook of Biochemistry with Clinical Correlations, Sixth Edition. Thomas M. Devlin, ed. Hoboken, NJ: Wiley-Liss, John Wiley & Sons, 2006, 1208 pp., $115.00, Hardcover. ISBN 0-471-67808-2. [PDF]
, 2006 Michael J. Bennett
openalex +1 more source
Essentials of Clinical Biochemistry [PDF]
Journal of Clinical Pathology, 1983 openaire +2 more sources
Molecular Oncology, EarlyView.This study identifies nuclear YB‐1 S102 phosphorylation as a marker associated with KRAS and FBXW7 mutations in colorectal cancer. Mutated KRAS correlates specifically with nuclear, not cytoplasmic, S102 YB‐1. These findings provide the first ex vivo evidence of this link in CRC and suggest future studies should assess the prognostic and therapeutic ...
Konstanze Lettau +9 more
wiley +1 more source
Proceedings of the Australasian Association of Clinical Biochemistry and Laboratory Medicine's 2020 Virtual Scientific Conference. [PDF]
Clin Biochem Rev, 2020 europepmc +1 more source
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Characteristics and Utilization of Biochemical Markers in Acute Coronary Syndromes [PDF]
, 2007 David A. Morrow +18 more
openalex +1 more source
A nucleotide‐independent, pan‐RAS‐targeted DARPin elicits anti‐tumor activity in a multimodal manner
Molecular Oncology, EarlyView.We report a Designed Ankyrin Repeat Protein that binds and inhibits RAS proteins, which serve as central cell signaling hubs and are essential for the progression of many cancers. Its unique feature is that it does not discriminate between different RAS isoforms or mutations and is capable of binding to RAS in both its active (GTP‐bound) and inactive ...
Jonas N. Kapp +13 more
wiley +1 more source
Molecular Oncology, EarlyView.C–C chemokine receptor type 9 (CCR9) is an immune checkpoint in pancreatic ductal adenocarcinoma (PDAC). Novel anti‐CCR9 antibody SRB2 was evaluated in combination with cytotoxic chemotherapy in PDAC cells, patient‐derived organoids, patient‐derived xenografts, and humanized mouse models.
Hannah G. McDonald +18 more
wiley +1 more source
9th Asian Pacific Congress of Clinical Biochemistry New Delhi, November 11–16, 2001
, 2001 Kumari Priyanka Sinha
openalex +4 more sources
Unraveling LINE‐1 retrotransposition in head and neck squamous cell carcinoma
Molecular Oncology, EarlyView.The novel RetroTest method allows the detection of L1 activation in clinical samples with low DNA input, providing global L1 activity and the identification of the L1 source element. We applied RetroTest to a real‐world cohort of HNSCC patients where we reported an early L1 activation, with more than 60% of T1 patients showing L1 activity.
Jenifer Brea‐Iglesias +12 more
wiley +1 more source